Ritu Baral - Canaccord
Hi guys, thanks for taking the follow-up, just one left quick question about when you guys go in front of CHMP, will your presentation be allowed to include data beyond the STAR trial? Will you be able to bring PRISM registry and clinical data from NUEDEXTA in other – not other indications but PBA secondary to other conditions other than MS, LS? Will you be able to bring that to the table?
Yes, as you know this is an iterative process as opposed to the NDA, right, so we’ve gone back and forth of multiple questions and answers over the past year. And they have seen pretty much all of the data that we know of any including post marketing data in the U.S. from a clinicians prescribing from case [ph] series, from other surveys of commission, the PRISM registry and so forth. And we will remind them of these data. In addition to that, we have contacted and have very important and experienced experts in PBA from Europe in addition to those in the U.S. who are joining us with the meeting. All of them are enthusiastic and then from the European standpoint would love to have a drug like NUEDEXTA to use in their patient safety PBA as it is right now, so they are very keen on seeing NUEDEXTA moving forward.
Sentiment: Strong Buy